Moderna Reports Positive Immunogenicity Data for Updated Spikevax Vaccine
ByAinvest
Tuesday, Sep 16, 2025 10:53 am ET1min read
MRNA--
The data, which follows recent reports linking vaccines to 25 child deaths based on unverified submissions to the Vaccine Adverse Event Reporting System, underscores the importance of transparency and accurate information in public health initiatives. The Vaccines for Children (VFC) program, supported by the US government, aims to enhance vaccination rates among underserved populations, thereby improving public health outcomes .
The US vaccine market, valued at approximately USD 30 billion, is driven by increasing public health initiatives, rising awareness of vaccine-preventable diseases, and advancements in vaccine technology. Key players such as Pfizer, Moderna, and Johnson & Johnson dominate the market due to their extensive research and development capabilities and established brand recognition [1].
The market is characterized by intense competition, with companies leveraging innovation, regulatory approvals, and strategic partnerships to enhance production and distribution efficiency. Despite challenges such as vaccine hesitancy and supply chain disruptions, the market is poised for substantial growth, driven by technological advancements and increased government support [1].
Moderna's updated Spikevax vaccine represents a significant advancement in the fight against COVID-19, highlighting the potential of mRNA technology in combating emerging infectious diseases. As new variants continue to emerge, the demand for innovative vaccines is expected to rise, particularly in the mRNA and combination vaccine segments [1].
Moderna has reported preliminary immunogenicity data for its updated Spikevax vaccine, showing an 8-fold increase in neutralizing antibodies against the LP.8.1 variant of SARS-CoV-2. The vaccine targets the currently dominant strains in the US and has a consistent safety profile. The update follows reports of Trump administration health officials linking vaccines to 25 child deaths, based on unverified submissions to the Vaccine Adverse Event Reporting System.
Moderna has announced preliminary immunogenicity data for its updated Spikevax vaccine, demonstrating an 8-fold increase in neutralizing antibodies against the LP.8.1 variant of SARS-CoV-2. This variant is currently dominant in the US, and the updated vaccine targets it effectively while maintaining a consistent safety profile [1].The data, which follows recent reports linking vaccines to 25 child deaths based on unverified submissions to the Vaccine Adverse Event Reporting System, underscores the importance of transparency and accurate information in public health initiatives. The Vaccines for Children (VFC) program, supported by the US government, aims to enhance vaccination rates among underserved populations, thereby improving public health outcomes .
The US vaccine market, valued at approximately USD 30 billion, is driven by increasing public health initiatives, rising awareness of vaccine-preventable diseases, and advancements in vaccine technology. Key players such as Pfizer, Moderna, and Johnson & Johnson dominate the market due to their extensive research and development capabilities and established brand recognition [1].
The market is characterized by intense competition, with companies leveraging innovation, regulatory approvals, and strategic partnerships to enhance production and distribution efficiency. Despite challenges such as vaccine hesitancy and supply chain disruptions, the market is poised for substantial growth, driven by technological advancements and increased government support [1].
Moderna's updated Spikevax vaccine represents a significant advancement in the fight against COVID-19, highlighting the potential of mRNA technology in combating emerging infectious diseases. As new variants continue to emerge, the demand for innovative vaccines is expected to rise, particularly in the mRNA and combination vaccine segments [1].
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet